Algoma Central Corp

The FDA approved Tryptyr (acoltremon ophthalmic solution) 0.003%, a first-in-class TRPM8 receptor agonist that stimulates corneal sensory nerves to rapidly increase natural tear production in dry eye disease patients.

Alcon has acquired a majority interest in Aurion Biotech, positioning itself at the forefront of ophthalmic cell therapy with AURN001, which has received Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA.

NovaBay Pharmaceuticals receives FDA clearance for Investigational New Drug application of NVC-422, triggering a $1 million milestone payment from licensing partner Alcon.

Alcon introduces Voyager DSLT, the first automated Direct Selective Laser Trabeculoplasty device, offering a groundbreaking first-line treatment option for nearly 5 million Americans with glaucoma.

Novartis' eye care division Alcon receives positive CHMP opinion for Jetrea (ocriplasmin) to treat vitreomacular traction and associated macular holes in European patients.

The ocular hypertension market is expanding due to increased prevalence of conditions affecting aqueous humor outflow, leading to elevated intraocular pressure (IOP).

Analysis of US ophthalmic clinical trials reveals key enrollment trends, aiding researchers in planning and resource allocation.

Following its 2019 spinoff from Novartis, Alcon successfully implemented Veeva Vault platform for clinical trials management, achieving 35% faster database delivery and 10-day median study lock times.

Wells Fargo maintained a Buy rating on Alcon (ALC) with a $105 price target, driven by the potential FDA approval of AR-15512 for dry eye.

Pantheon Vision, led by industry veteran John Sheets, PhD, is developing innovative bioengineered alternatives to traditional corneal transplants to address global corneal blindness.